Buy GLP-3 R (Retatrutide) Online — GLP Weight-Loss Peptide
Triple Receptor Agonist — Next-Level Weight Loss
Last updated April 2026 · COA-verified
Buy GLP-3 R (Retatrutide) — Retatrutide (GLP-3 R) is a triple GLP-1/GIP/glucagon receptor agonist showing 24% body weight reduction in Phase II — the most potent weight loss peptide in clinical development.
- 24.2% body weight reduction in Phase II trial at 48 weeks — unprecedented
- Triple GLP-1/GIP/glucagon receptor agonism — three simultaneous weight loss mechanisms
- Glucagon agonism raises basal metabolic rate — burns more calories at rest
- Significant reduction in liver fat (NASH-relevant)
- Reduces triglycerides and blood pressure in addition to weight
COA verified · US domestic shipping
Retatrutide (GLP-3 R): The Triple Receptor Agonist Rewriting Weight Loss Science
24% Weight Reduction
Phase II results: 24.2% body weight reduction at 48 weeks — with no plateau. The highest weight loss ever demonstrated in a clinical trial at that point.
Triple Mechanism
GLP-1 + GIP + glucagon receptor activation — the glucagon component raises basal metabolic rate and drives liver fat oxidation beyond what dual agonists achieve.
Liver Fat Reduction
Significant hepatic fat reduction — making retatrutide potentially the first anti-obesity agent with strong NASH (liver disease) efficacy simultaneously.
No Plateau
Unlike semaglutide, retatrutide showed continued weight loss trajectory at 48 weeks with no plateau — suggesting even greater efficacy over longer treatment.
What Trial Subjects Actually Lost on Retatrutide
- 24.2% body weight reduction in Phase II trial at 48 weeks — unprecedented
- Triple GLP-1/GIP/glucagon receptor agonism — three simultaneous weight loss mechanisms
- Glucagon agonism raises basal metabolic rate — burns more calories at rest
- Significant reduction in liver fat (NASH-relevant)
- Reduces triglycerides and blood pressure in addition to weight
- No weight loss plateau observed at 48 weeks — continued trajectory
- Most advanced compound in pipeline for obesity treatment
- Phase III trials underway with high probability of approval
The Four-Step Retatrutide Ladder
Phase II Escalation Protocol (Reference):
• 2mg weekly × 4 weeks
• 4mg weekly × 4 weeks
• 8mg weekly × 4 weeks
• 12mg weekly (maintenance)
Injection: Once weekly subcutaneous.
Note: Phase III compound. Clinical data pending.
Retatrutide: Triple Receptor Mechanism Explorer
Retatrutide activates three receptors simultaneously. Select each to understand its unique contribution to the 24% weight loss result.
GLP-1 Receptor — What It Does
Appetite Suppression
Acts on hypothalamic GLP-1 receptors to reduce hunger signals and extend satiety between meals.
Gastric Emptying
Slows gastric emptying, extending the satiety signal from meals and improving post-meal glucose control.
Insulin Secretion
Glucose-dependent insulin stimulation — only triggers insulin release when blood glucose is elevated, minimizing hypoglycemia risk.
Clinical Context
Shared mechanism with semaglutide. Contributes ~15% weight loss on its own.
(GLP-1 only)
(GLP-1 + GIP)
(GLP-1 + GIP + Glucagon)
Phase II data. Phase III ongoing. For research and educational purposes only.
Why the Glucagon Arm Changes Everything
Retatrutide is a triple receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors — representing the next frontier beyond dual agonists like tirzepatide. It is in late-stage clinical development and has already demonstrated the most impressive weight loss data in clinical trial history.
▸Triple Mechanism
Adding glucagon receptor agonism to the GIP+GLP-1 mechanism introduces a third metabolic pathway:
▸Glucagon receptor:
→Directly stimulates hepatic fat burning (liver fat oxidation)
→Increases basal energy expenditure (raises metabolic rate)
→Promotes lipolysis in adipose tissue
→Reduces hepatic fat accumulation
This addition explains why retatrutide outperforms tirzepatide in weight loss efficacy.
▸Phase II Trial Results
In the Phase II trial (N Engl J Med, 2023):
→24.2% body weight reduction at 48 weeks (highest dose)
→Continued weight loss trend at week 48 with no plateau in sight
→Superior to tirzepatide data at comparable timepoints
→Significant reductions in liver fat, triglycerides, and blood pressure
▸Where It Stands
Retatrutide is currently in Phase III trials. If results hold, it will represent the most effective obesity therapy ever developed by a substantial margin.
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available for all products.
GLP-3 R (Retatrutide)
COA verified · Third-party tested · US domestic shipping
Buy Now View Stack ProtocolsGLP receptor agonists work via hypothalamic appetite regulation and metabolic enhancement — proven in large-scale clinical trials.
All Weight Loss PeptidesStacks Best With
Peptides to Support a Retatrutide Protocol
Anti-AgingNAD+ 500mg
Cellular Energy & Longevity Cofactor
Verified NAD+ 500mg — NAD+ is the master cellular energy molecule that declines 50% by age 50 — supplementation restores sirtuin activity, DNA repair, and mitochondrial function.
Weight LossGLP-1 S (Semaglutide)
Next-Gen GLP-1 Receptor Agonist for Weight Loss
Trusted GLP-1 S (Semaglutide) — Semaglutide (GLP-1 S) is a GLP-1 receptor agonist with clinical trials showing 15-20% body weight reduction — the most effective pharmacological weight loss agent studied.
Weight LossGLP-2 T (Tirzepatide)
Dual GIP/GLP-1 Agonist — Superior Weight Loss
Verified GLP-2 T (Tirzepatide) — Tirzepatide (GLP-2 T) is a dual GIP/GLP-1 receptor agonist showing up to 22.5% body weight reduction in trials — outperforming semaglutide in head-to-head data.